Association of CYP1B1 polymorphisms with breast cancer: A case-control study in the han population in Ningxia Hui autonomous region, P. R. China

Biomarker Insights

Volumn 2010, Issue 5, 2010, Pages 21-27

  Jiao, Haiyan ^a,b   Liu, Chunlian ^c   Guo, Weidong ^c   Peng, Liang ^a,b   Chen, Yintao ^a,b   Martin, Francis L ^d  

^a NINGXIA MEDICAL UNIVERSITY   (China)

^b Key Laboratory of Reproduction and Genetics of Ningxia Hui Antonomous Region   (China)

^c AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY   (China)

^d LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; CYP1B1; Han population; Ningxia (China); Phase I metabolism; Polymorphism

Indexed keywords

ALANINE; CYTOCHROME P450 1B1; DNA FRAGMENT; GENOMIC DNA; GUANINE; LEUCINE; SERINE; THYMINE; VALINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER RISK; CHINA; CHINESE; CODON; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HAN POPULATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; NUCLEIC ACID BASE SUBSTITUTION; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; RURAL AREA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77951272548     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/bmi.s4094     Document Type: Article

References (30)

1. Martin FL. Genotoxins and the initiation of sporadic breast cancer. Mutagenesis. 2001;16:155-61.
2. Yared E, McMillan TJ, Martin FL. Genotoxic effects of oestrogens in breast cells detected by the micronucleus assay and the Comet assay. Mutagenesis. 2002;17:345-52.
3. Martin FL, Carmichael PL, Crofton-Sleigh C, et al. Genotoxicity of human mammary lipid. Cancer Res. 1996;56:5342-6.
4. Carnell DM, Smith RE, Daley FM, et al. Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int J Radiat Oncol Biol Phys. 2004;58:500-9.
5. McFadyen MCE, Melvin WT, Murray GI. Cytochrome P450 enzymes: Novel options for cancer therapeutics. Mol Cancer Ther. 2004;3:363-71.
6. Ragavan N, Hewitt R, Cooper LJ, et al. CYP1B1 expression in prostate is higher in the peripheral than in the transition zone. Cancer Lett. 2004;215:69-78.
7. John K, Ragavan N, Pratt MM, et al. Quantification of phase I/II metabolizing enzyme gene expression and polycyclic aromatic hydrocarbon-DNA adduct levels in human prostate. Prostate. 2009;69:505-19.
8. McKay JA, Melvin WT, Ah-See AK, et al. Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Lett. 1995;374:270-2.
9. McFadyen MC, Breeman S, Payne S, et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem. 1999;47:1457-64.
10. Singh PB, Matanhelia SS, Martin FL. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer. 2008;44:928-36.
11. Hayes CL, Spink DC, Spink BC, et al. 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A. 1996;93: 9776-81.
12. Miyoshi Y, Noguchi S. Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women. Biomed Pharmacother. 2003;57:471-81.
13. Sillanpää P, Heikinheimo L, Kataja V, et al. CYP1A1 and CYP1B1 genetic polymorphisms, smoking and breast cancer risk in a Finnish Caucasian population. Breast Cancer Res Treat. 2007;104:287-97.
14. Nock NL, Tang D, Rundle A, et al. Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race. Cancer Epidemiol Biomarkers Prev. 2007;16:1236-45.
15. Bejjani BA, Lewis RA, Tomey KF, et al. Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia. Am J Hum Genet. 1998;62:325-33.
16. Lee KM, Abel J, Ko Y, et al. Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women. Br J Cancer. 2003;88:675-8.
17. Saintot M, Malaveille C, Hautefeuille A, et al. Interactions between genetic polymorphism of cytochrome P450-1B1, sulfotransferase 1A1, catechol-Omethyltransferase and tobacco exposure in breast cancer risk. Int J Cancer. 2003;107:652-7.
18. Zheng W, Xie DW, Jin F, et al. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:147-50.
19. Thyagarajan B, Brott M, Mink P, et al. CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study. Cancer Lett. 2004;207:183-9.
20. Liu C, Gu J, Peng L, et al. Research on Breast Cancer Genetic Susceptibility Associated with CYP1B1 SNPrs1056836, ER and PR in Ningxia Han Population. Bull Chinese Cancer. 2009;18:31-3.
21. Watanabe J, Shimada T, Gillam EM, et al. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics. 2000;10:25-33.
22. Wen W, Cai Q, Shu XO, et al. Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the shanghai breast cancer study and a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2005;14:329-35.
23. Bailey LR, Roodi N, Dupont WD, et al. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 1998;58:5038-41.
24. Gaudet MM, Chanock S, Lissowska J, et al. Genetic variation of cytochrome P450 1B1 (CYP1B1) and risk of breast cancer among Polish women. Pharmacogenet Genomics. 2006;16:547-53.
25. Tang YM, Green BL, Chen GF, et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics. 2000;10:761-6.
26. Listgarten J, Damaraju S, Poulin B, et al. Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. Clin Cancer Res. 2004;10:2725-37.
27. Paracchini V, Raimondi S, Gram IT, et al. Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am J Epidemiol. 2007;165:115-25.
28. De Vivo I, Hankinson SE, Li L, et al. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11: 489-92.
29. Singh PB, Ragavan N, Ashton KM, et al. Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study. Asian J Androl. 2010;12:203-14. doi: 10.1038/aja.2009.71 [Online 23 November 2009].
30. Taylor SE, Martin-Hirsch PL, Martin FL. Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Lett. 2010;288:133-48. doi: 10.1016/ j.canlet.2009.06.017 [Online 15 July 2009].